Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 511-519

  Angelova, Assia L ^a   Aprahamian, Marc ^c   Grekova, Svitlana P ^a   Hajri, Amor ^c   Leuchs, Barbara ^a   Giese, Nathalia A ^b   Dinsart, Christiane ^a   Herrmann, Alexia ^a   Balboni, Ginette ^c   Rommelaere, Jean ^a   Raykov, Zahari ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; GEMCITABINE; ONCOLYTIC PARVOVIRUS; ONCOLYTIC PARVOVIRUS H 1PV; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG SENSITIVITY; HUMAN; HUMAN CELL; KIDNEY FUNCTION; LEWIS RAT; LIVER FUNCTION; MALE; METASTASIS; MICRO-COMPUTED TOMOGRAPHY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RAT; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; CELL LINE, TUMOR; DEOXYCYTIDINE; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS; PARVOVIRUS; RATS; RATS, INBRED LEW;

EID: 59449089665     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1088     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. Cancer J Clin 2007;57:43-66.
2. Finlayson E, Birkmeyer JD. Effects of hospital volume on life expectancy after selected cancer operations in older adults: a decision analysis. J Am Coll Surg 2003;196:410-7.
3. Ghaneh P, Smith R, Tudor-Smith C, et al. Neoadjuvant and adjuvant strategies for pancreatic cancer. Eur J Surg Oncol 2007;34:297-305.
4. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
5. Giovannetti E, Mey V, Nannizzi S, et al. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 2006;5:1387-95.
6. Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/ II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003;9:555-61.
7. Rommelaere J, Cornells J. Antineoplastic activity of parvoviruses. J Virol Methods 1991;33:233-51.
8. Cotmore SF, Tattersall P. The autonomously replicating parvoviruses of vertebrates. Adv Virus Res 1987; 33:91-174.
9. Haag A, Menten P, Van Damme J, et al. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum GeneTher 2000;11:597-609.
10. Russell SJ, Brandenburger A, Flemming CL, et al. Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. J Virol 1992:66:2821 -8.
11. Olijslagers S, Dege AY, Dinsart C, et al. Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin. Cancer Gene Ther 2001;8:958-65.
12. Di Piazza M, Mader C, Geletneky K, et al. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol 2007;81:4186-98.
13. Evrard S, Keller P, Hajri A, et al. Experimental pancreatic cancer in the rat treated by photodynamic therapy. Br J Surg 1994;81:1185-9.
14. Wrzesinski C, Tesfay L, Salomé N, et al. Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells. J Virol 2003;77:3851 -8.
15. Giese NA, Raykov Z, DeMartino L, et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer GeneTher 2002;9:432-42.
16. Schaarschmidt T, Merkord J, Adam U, et al. Expression of multidrug resistance proteins in rat and human chronic pancreatitis. Pancreas 2004;28:45-52.
17. Mutter D, Hajri A, Tassetti V, et al. Increased tumor growth and spread after laparoscopy vs laparotomy: influence of tumor manipulation in a rat model. Surg Endosc 1999;13:365-70.
18. Bennett JJ, Adusumilli P, Petrowsky H, et al. Up- regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 2004; 18:1001-3.
19. Raykov Z, Balboni G, Aprahamian M, et al. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 2004;109:742-9.
20. Shi X, Liu S, Kleeff J, et al. Acquired resistance of pancreatic cancer cells towards 5 -fluorouracil and gemcitabine is associated with altered expression of apoptosis- regulating genes. Oncology 2002;62:354-62.
21. Kasuya H, Nishiyama Y, Nomoto S, et al. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer GeneTher 2007;14:533-42.
22. Freytag SO, Barton KN, Brown SL, et al. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 2007;15:1600-6.
23. Halloran CM, Ghaneh P, Shore S, et al. 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. J Gene Med 2004;6:514-25.
24. Prestwich RJ, Harrington KJ, Vile RG, Melcher A A. Immunotherapeutic potential of oncolytic virotherapy. Lancet Oncol 2008;9:610-2.
25. Raykov Z, Grekova S, Galabov AS, et al. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol Rep 2007;17: 1493-9.
26. Plate JM, Plate AE, Shott S, et al. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 2005:54:915-25.
27. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002;62:2353-8.